{"analyses":[{"ciLowerLimit":"0.551","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.754","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.64"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.8","upperLimit":"34.6","value":"30.4"},{"groupId":"OG001","lowerLimit":"17.0","upperLimit":"22.4","value":"19.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \\> of at least 5 mm. The appearance of one or more new lesions was also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)","title":"Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Months"}